Table 4.
Random effects meta-analyses results between PDCI and HCs subjects.
| Region | Number of studies | Subjects | SMD | [95% CI] | Overall effect | Heterogeneity | |||
|---|---|---|---|---|---|---|---|---|---|
| PDCl | HCs | Z | P | I 2 [%] | P | ||||
| Entorhinal | 3 | 101 | 208 | 0.059 | [−0.181, 0.299] | 0.48 | 0.630 | 0 | 0.934 |
| Hippocampus | 2 | 31 | 48 | −0.357 | [−0.821, 0.107] | 1.51 | 0.132 | 0 | 0.549 |
| Sup.temporal lobe | 2 | 31 | 48 | 0.033 | [−0.458, 0.524] | 0.13 | 0.894 | 10.1 | 0.292 |
| Mid-inf.temporal lobe | 2 | 31 | 48 | 0.275 | [−0.188, 0.737] | 1.16 | 0.244 | 0 | 0.581 |
| Inf.temporal lobe | 3 | 100 | 214 | 1.583 | [0.049, 3.116] | 2.02 | 0.043 | 94.8 | 0 |
| Precuneus | 3 | 39 | 77 | 1.838 | [−0.413, 4.089] | 1.60 | 0.109 | 95.21 | 0 |
PDCI, Parkinson's disease with cognitive impairment; HCs, healthy controls; SMD, Standardized mean difference; CI, confidence interval. The bold values indicate the value of P < 0.05.